FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/08/2026
Voltar para busca
Dado oficial do USPTO
AUTOLUS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
22
Atualização mais recente
06/08/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 40, 42, 44
Data de depósito
27/01/2025
Data de registro
13/01/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/01/2026
Última transação
06/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
GB
Examinador
HARMON, RAYMOND E
Unidade examinadora
L30
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "AUTOLUS" where a design of a shaded circle with a smaller circle carving out a space in its upper-left takes the place of the letter "O".
Titulares e representantes
Titulares
Autolus Limited
Representantes
Rebecca Liebowitz Venable LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medical and veterinary preparations for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases for therapeutic purposes; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; pharmaceutical preparations for cancer therapies; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treatment of cancer comprising chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies for medical purposes; pharmaceutical preparations for genetically modifying human or animal cells for medical purposesin particular viral vectors; pharmaceutical preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes for the treatment of cancergenetic conditionsimmune response disordersautoimmune disordersinfectious diseasesophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseases and cardiovascular diseases; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapyin particular T cell therapy; vaccines
Classe 40
Custom manufacture of therapeutic drugsnamely cell therapiespreparations to treat autoimmune diseasescancer therapies and cancer vaccines
Classe 42
Scientific and technological services and research and design relating theretomedical researchscientific researchanalysis and testing in the field of human and animal cellgene and cancer therapiespharmaceutical product developmentresearch and development of new products; industrial analysis and research services in the field of cellgene and cancer therapies; medical and veterinary research servicesin particular in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccinesin particular personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services
Classe 44
Medical services; veterinary services; medical services for the extraction of human and animal cells from patients; medical servicesmanipulation of human and animal cells for therapeutic purposes; medical servicesreinsertion of cells into human and animal patients; medical and veterinary servicesproviding advice and consultancy in the field of medical and veterinary therapies; medical and veterinary servicesproviding advice and consultancy in the field of autoimmune diseasescancer therapies and cancer vaccines
Publicações
Histórico de despachos e eventos da marca no USPTO.
22 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
19/07/2026
FIMP
FINAL DISPOSITION PROCESSED
19/07/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/04/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
13/01/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
13/01/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/11/2025
PUBO
PUBLISHED FOR OPPOSITION
25/11/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/10/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/10/2025
RFNT
REFUSAL PROCESSED BY IB
12/07/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/06/2025
RFRR
REFUSAL PROCESSED BY MPU
21/06/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/04/2025
CNRT
NON-FINAL ACTION WRITTEN
17/04/2025
DOCK
ASSIGNED TO EXAMINER
09/04/2025
MAFR
APPLICATION FILING RECEIPT MAILED
04/04/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/04/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/04/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AUTOLUS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.